Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04498377
Recruitment Status : Recruiting
First Posted : August 4, 2020
Last Update Posted : January 28, 2021
Sponsor:
Information provided by (Responsible Party):
Generon (Shanghai) Corporation Ltd.

Brief Summary:
This is an interventional, multicenter, 2-arm, parallel-group, randomized, double-blind, placebo controlled, dose-escalation, safety and efficacy study of F-652 treatment versus placebo in patients aged 18 years or older with a COVID-19 diagnosis confirmed by PCR. Eligible patients will have moderate to severe COVID-19 symptoms within 5 days post hospitalization and a positive COVID-19 testing.

Condition or disease Intervention/treatment Phase
Covid19 Biological: F-652 Biological: Placebo Phase 2

Detailed Description:

The study is planned to include 4 cohorts, with enrolled patients being randomized 1:1 in a blinded manner on Day 1, following screening, to F-652 or placebo as follows:

  • Cohort 1 (sentinel cohort): Four patients will receive either dose level 1 F-652 or placebo. Upon completion of sentinel, the Data Monitoring Committee will evaluate the safety and tolerability data of the sentinel patients and determine if it is acceptable to dose the remaining patients in this dosing group in Cohort 2.
  • Cohort 2: Fourteen patients will receive either dose level 1 F-652 or placebo. Upon completion of Cohort 2, the DMC will convene and review all available safety data to determine if the study can proceed to the next dose level.
  • Cohort 3 (sentinel cohort): Four patients will receive either dose level 2 F-652 or placebo. Upon completion of sentinel dosing, the DMC will evaluate the safety and tolerability data of the sentinel patients and determine if it is acceptable to dose the remaining patients in this dosing group in Cohort 4.
  • Cohort 4: Sixteen patients will receive either dose level 2 F-652 or placebo. Treatment will begin on Day 1 following randomization. Patients assigned to active drug will receive a total of 2 doses of F-652 (1 IV infusion on Day 1 and 1 IV infusion on Day 8). Patients assigned to placebo will receive identical IV infusions of placebo vehicle on Days 1 and 8. All patients will receive available supportive and antiviral therapies as standard of care. Efficacy will be assessed on Days 15 and 29. Patients will be followed for safety until Day 60.

The primary efficacy endpoint is the proportion of patients with a ≥2-point increase in the National Institute of Allergy and Infectious Diseases (NIAID) 8-point ordinal scale from baseline to Day 29.

The secondary efficacy endpoints include the proportion of patients with a ≥2-point increase in the NIAID 8-point ordinal scale from baseline to Day 15, mortality rate by Days 15 and 29, percentage of patients who have recovered and discharged from the hospital by Days 15 and 29, and percentage of patients progressed to severe/critical disease by Day 15.

The safety endpoints include all cause treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs); change from screening (baseline) in clinical symptoms and abnormal vital signs, abnormal laboratory tests; and relationship of any AEs with F-652 treatment.

The exploratory endpoints include time to negative SARS-CoV-2 PCR test from randomization; and changes in pharmacodynamic parameters.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 38 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:

Patients will be randomized in a 1:1 ratio in a double-blind manner to receive F-652 or placebo.

An independent statistician from Medpace will generate the randomization schedule. Patients meeting eligibility criteria will be randomized on Day 1 in a 1:1 ratio to F-652 or placebo, respectively. Patients will be assigned a randomization number and treatment assignment according to the randomization schedule. This randomization schedule will be maintained by the investigative site pharmacist until it is appropriate to break the blind. The Investigator, investigative site personnel (except site-designated pharmacist and dedicated assistant), study monitors, vendors, Sponsor, and Medpace will remain blinded to treatment assignment.

Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Multicenter Study to Evaluate the Efficacy and Safety of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19
Actual Study Start Date : January 26, 2021
Estimated Primary Completion Date : September 30, 2021
Estimated Study Completion Date : December 31, 2021

Arm Intervention/treatment
Experimental: F-652 Biological: F-652
IL-22 fusion protein administered intravenously

Placebo Comparator: Placebo Biological: Placebo
Placebo administered intravenously




Primary Outcome Measures :
  1. NIAID 8-point ordinal scale [ Time Frame: Study day 1 before dose to day 29 ]
    The proportion of patients with a greater or equal 2-point change in the NIAID 8-point ordinal scale from baseline to Day 29



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Willing to provide informed consent and able to comply with protocol requirements
  • 18 years or older
  • Has a COVID-19 diagnosis confirmed by PCR
  • Hospitalized within 5 days and meets the following criteria at screening:

Peripheral capillary oxygen saturation (SpO2) ≤ 93% on room air or SpO2 ≥93% on ≤10 liters per minute of supplemental oxygen via nasal cannula

  • Radiographic (chest X-ray, computed tomography scan, or ultrasound) evidence of bilateral pulmonary infiltrates consistent with SARS-CoV-2/COVID-19
  • Clinical symptoms consistent with COVID-19 per Investigator judgement
  • Body mass index between 18 to 40 kg/m2
  • If of reproductive potential, willing to abstain or agree to the use of highly effective contraception

Exclusion Criteria:

  • Respiratory failure at screening
  • History of heart failure
  • History of COPD or bronchial asthma
  • Active TB or history of TB of the following types
  • Uncontrolled arrhythmia within 3 months prior to randomization
  • Heart disease of the following types
  • Moderate to severe renal insufficiency
  • Abnormal white cell and platelet counts
  • History of transplantation of vital organs (e.g., heart, lung, liver, and/or kidney);
  • Malignant tumor
  • Uncontrolled systemic or local autoimmune or inflammatory disease besides SARS-CoV-2
  • Unhealed wounds, active gastric ulcer, had surgery
  • Received other investigational therapeutic products
  • Used interferon therapies
  • History of HIV infection, hepatitis B, and/or hepatitis C
  • Known serious allergic reaction or hypersensitivity to components of F-652
  • Pregnant or breastfeeding
  • History of drug abuse or use of narcotics
  • Treated with immunomodulators or immunosuppressants
  • Other conditions resulting in increased risk

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04498377


Contacts
Layout table for location contacts
Contact: William L Daley, MD 908-845-9619 william.daley@evivebiotech.com

Locations
Layout table for location information
United States, Louisiana
Tulane University School of Medicine Recruiting
New Orleans, Louisiana, United States, 70112
Contact: Cynthia Moreau, RN       cmoreau@tulane.edu   
Principal Investigator: Christine Bojanowski, MD         
Sponsors and Collaborators
Generon (Shanghai) Corporation Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Christine M Bojanowski, MD Tulane University
Layout table for additonal information
Responsible Party: Generon (Shanghai) Corporation Ltd.
ClinicalTrials.gov Identifier: NCT04498377    
Other Study ID Numbers: GC-652-04
First Posted: August 4, 2020    Key Record Dates
Last Update Posted: January 28, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No